Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Optinose Expects XHANCE Net Revenues For FY24 To Be Between $85M-$95M; Sees Average XHANCE Net Revenue Per Prescription To Exceed $230 (Prior View: $220)

Author: Benzinga Newsdesk | May 14, 2024 07:07am

Operating Expenses
The Company expects total GAAP operating expenses (selling, general & administrative expenses and research & development expenses) for 2024 to be between $95.0 to $101.0 million, of which the Company expects stock-based compensation to be approximately $6.0 million.

Net Income from Operations
The Company expects to product positive income from operations (GAAP) for full year 2025.

Posted In: OPTN